Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 4
1993 3
1994 4
1995 8
1996 6
1997 5
1998 13
1999 27
2000 42
2001 41
2002 72
2003 83
2004 70
2005 91
2006 74
2007 72
2008 89
2009 63
2010 68
2011 71
2012 91
2013 75
2014 83
2015 70
2016 77
2017 57
2018 52
2019 59
2020 66
2021 56
2022 65
2023 51
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,581 results

Results by year

Filters applied: . Clear all
Page 1
Rabeprazole.
[No authors listed] [No authors listed] 2022 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000341 Free Books & Documents. Review.
Because no information is available on the use of rabeprazole during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant....
Because no information is available on the use of rabeprazole during breastfeeding, an alternate drug may be preferred, especially wh …
Rabeprazole.
[No authors listed] [No authors listed] 2019 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643484 Free Books & Documents. Review.
Rabeprazole is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity used in the therapy of gastroesophageal reflux and peptic ulcer disease. Rabeprazole therapy is associated with a low rate of transient and asymptomatic serum aminotransferase ele …
Rabeprazole is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity used in the therapy of gastroesophageal reflux …
Rabeprazole.
Prakash A, Faulds D. Prakash A, et al. Drugs. 1998 Feb;55(2):261-7; discussion 268. doi: 10.2165/00003495-199855020-00009. Drugs. 1998. PMID: 9506245 Review.
Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition of the proton pump by rabeprazole is partially reversible. Rabeprazole has 2- to 10-fold greater antisecretory activity than o …
Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition …
Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Ochoa D, Román M, Cabaleiro T, Saiz-Rodríguez M, Mejía G, Abad-Santos F. Ochoa D, et al. BMC Pharmacol Toxicol. 2020 Jul 25;21(1):54. doi: 10.1186/s40360-020-00433-2. BMC Pharmacol Toxicol. 2020. PMID: 32711578 Free PMC article. Clinical Trial.
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clinical trials. METHOD: Subjects were evaluated to determine the …
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study popu …
Rabeprazole: A comprehensive profile.
Bakheit AH, Al-Kahtani HM, Albraiki S. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:137-183. doi: 10.1016/bs.podrm.2020.07.003. Epub 2020 Aug 13. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461697
Rabeprazole belongs to the class of anti-secretory drugs, with benzimidazoles substitution. ...This effect helps to treat and prevent conditions in which gastric acid directly aggravates symptoms such as duodenal and gastric ulcers. This chapter includes a comprehensive re …
Rabeprazole belongs to the class of anti-secretory drugs, with benzimidazoles substitution. ...This effect helps to treat and prevent …
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Sakurai Y, et al. Aliment Pharmacol Ther. 2015 Sep;42(6):719-30. doi: 10.1111/apt.13325. Epub 2015 Jul 21. Aliment Pharmacol Ther. 2015. PMID: 26193978 Free article. Clinical Trial.
METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or rabeprazole 10 mg (Study V vs. R) were orally administered daily for 7 days. ...RESULTS: Acid-inhibitory effect (pH4 HTR) of vonoprazan was sign …
METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or rabepraz …
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Çelebi A, et al. Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514. Turk J Gastroenterol. 2016. PMID: 27782887 Free article. Clinical Trial.
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was found to have the most rapid action, followed by lansoprazole …
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time …
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ, Andersson TB, Ahlström M, Weidolf L. Li XQ, et al. Drug Metab Dispos. 2004 Aug;32(8):821-7. doi: 10.1124/dmd.32.8.821. Drug Metab Dispos. 2004. PMID: 15258107
., omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole) as inhibitors of four cytochrome P450 enzymes (CYP2C9, 2C19, 2D6, and 3A4), we performed in vitro studies using human liver microsomal preparations and recombinant CYP2C19. ...The inhibitory potency …
., omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole) as inhibitors of four cytochrome P450 enzymes (CYP2C9, 2C19 …
Rabeprazole for the treatment of acid-related disorders.
Marelli S, Pace F. Marelli S, et al. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):423-35. doi: 10.1586/egh.12.18. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22928894 Review.
Proton pump inhibitors are widely used for the treatment of acid-related disorders. Rabeprazole is a potent and irreversible inhibitor of H(+)/K(+)-ATPase gastric pump, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger Ellison syndrome, du …
Proton pump inhibitors are widely used for the treatment of acid-related disorders. Rabeprazole is a potent and irreversible inhibito …
Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Dash RP, Rais R, Srinivas NR. Dash RP, et al. Xenobiotica. 2018 Apr;48(4):422-432. doi: 10.1080/00498254.2017.1307470. Epub 2017 Apr 6. Xenobiotica. 2018. PMID: 28294690 Review.
One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition. 4. The review was aimed to provide pharmacokinetic data of rabeprazole from several clinical studies including d …
One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmaco …
1,581 results